Targeted anti-IL-13 therapies in asthma: current data and future perspectives
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Investigational Drugs"
DOI: 10.1080/13543784.2018.1427729
Abstract: ABSTRACT Introduction: The identification of patients with severe asthma who will benefit from a personalized management approach remains an unmet need. Interleukin-13 (IL-13) is a cytokine possessing a significant role in asthma pathogenesis and progression… read more here.
Keywords: targeted anti; therapies asthma; severe asthma; asthma current ... See more keywords
Anti-IL-6 therapies in central nervous system inflammatory demyelinating diseases
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.966766
Abstract: Current treatments for central nervous system (CNS) inflammatory demyelinating diseases (IDDs) include corticosteroids, plasma exchange, intravenous immunoglobulin, and immunosuppressant drugs. However, some patients do not respond well to traditional therapies. In recent years, novel drugs,… read more here.
Keywords: central nervous; anti therapies; nervous system; demyelinating diseases ... See more keywords